Glaukos, Intratus add presbyopia indication to licensing agreement
Glaukos and Intratus have amended a global licensing agreement to include the treatment of presbyopia, according to a Glaukos press release.
The amendment adds presbyopia as an investigational application to the Eyelid Drug Delivery Platform. Glaukos will have a global exclusive license to research, develop, manufacture and commercialize Intratus’ delivery system for presbyopia treatment, the release said. Previously, Glaukos had licensing of the platform for the treatment of dry eye disease, glaucoma and other corneal disorders.
“We are excited to expand our partnership with Intratus by adding presbyopia as a new investigational application for this novel drug delivery platform and build upon the promising R&D work we’ve completed thus far in dry eye disease, glaucoma and other corneal disorders,” Thomas Burns, Glaukos president and CEO, said in the release.
With the platform, “patented cream-based drug formulations are applied to the outer surface of the eyelid for transdermal delivery of pharmaceutically active compounds for the treatment of eye disorders,” the release said.
Glaukos and Intratus reached the original agreement in 2019. Financial terms of the amendment were not released.
Read more about